Artificial Intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results

Abstract

<title>Abstract</title> Short-term androgen deprivation therapy (ST-ADT) improves outcomes for intermediate-risk prostate cancer (IR-PC) but has toxicity. This trial assesses multimodal AI (MMAI) biomarkers in ST-ADT decision-making for men receiving radiotherapy. We report interim results from 200 patients. MMAI testing significantly impacted shared decisions, with 70.3% of patients initially opting for ST-ADT changing decision to forgo ADT (p&lt;0.001). Use of these biomarkers have led to reduced ST-ADT use and better-informed management.

Ähnliche Arbeiten